CS Paper Radar

TrialDesignBench: Benchmarking Language Models for Phase-I Trial Design Against Clinical Knowledge

Yihan Hank Tang, Peng Yang, Jiayi Xin, Tianqi Shang, Xuyang Chen, Ying Yuan, Yi Lian, Qi Long

cs.AI cs.CLstat.AP ·submitted 2026-11-09 16:15 UTC · v1
publishedbenchmarkcode/data

Abstract

AI is used in much of the clinical trial pipeline. However, selecting the statistical design of a trial, a crucial step that determines how drug doses are tested on humans and evaluated, has seen almost no AI progress. LLMs appear to be a natural fit given their strengths in biomedical knowledge and statistical reasoning. Nevertheless, there is currently no appropriate way to evaluate such abilities because recent regulatory and methodological shifts, most notably FDA's Project Optimus, have redefined what constitutes a reasonable design and rendered many previous designs obsolete. To lay the groundwork for AI-assisted trial design, we introduce TrialDesignBench, a benchmark of 617 Phase-I/I-II oncology dose-finding trials, each paired with an expert-validated reference design that is consistent with the latest FDA regulatory initiatives. This reference standard is produced through a formalization of the expert design process. We evaluate five frontier LLMs, none of which matches the reference standard. Our ablation experiments trace this performance gap to two main causes, inference of latent, unrecorded design determinants from trial sources (supplying them raises class-wise balanced accuracy by 0.22) and structured decision-tree reasoning (+0.24). TrialDesignBench offers a reproducible, contemporary-standard objective for evaluating and enhancing AI-assisted trial design.

Comment
13 pages, 3 figures, 6 tables. Presented as a poster at the NeurIPS 2026 Workshop on World Models for High-Stakes Health (WMHS). Code and data: https://github.com/hanktang-research/TrialDesignBench

Closest papers

Nearest neighbours by meaning across the whole index.

TrialAtlas: Multi-Agent Research Organization for Clinical Trial Design and Optimization

cs.CL ·2026-09-18 ·Jiacheng Lin, Zifeng Wang, Zheng Chen, Erick Scott, Ziwei Yang +3 more
similarity 0.74
Abstract

Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely on clinical development planning (CDP) and probability of technical and regulatory success assessment to anticipate development risks, yet these decisions remain labor-intensive and subjective, requiring experts across clinical science, statistics, regulatory affairs, and competitive intelligence to jointly acquire, synthesize, and reason over heterogeneous evidence. Here, we introduce TrialAtlas, a memory-augmented multi-agent research organization for CDP that mirrors this collaborative process by coordinating specialized agents for literature synthesis, competitive trial intelligence, regulatory precedent analysis, and integrated reasoning over trial design and development risk. TrialAtlas further learns from historical clinical trials and regulatory outcomes, including prior New Drug Applications (NDAs), to ground its decisions in accumulated development experience. To evaluate these capabilities in an authentic regulatory setting, we introduce TrialAtlasBench, constructed from 291 FDA Complete Response Letters and spanning three practical tasks: detecting trial design deficiencies, recommending actionable design improvements, and predicting technical and regulatory success. TrialAtlas achieves an F1 score of 50.0% for deficiency detection, outperforming the strongest baseline by 6.1 points, and reaches 85.3% balanced accuracy and 84.7% F1 for prediction of technical and regulatory success, improving over the best baselines by 6.7 points in balanced accuracy and 12.0 points in Cohen's kappa. In expert evaluation, 86.4% of TrialAtlas-generated concerns were judged valid, compared with 83.1% for OpenAI DeepResearch and 59.3% for Gemini DeepResearch.

0.40

Advancing Clinical Trial Outcome Prediction with Domain-Specific Large Language Models

cs.AI ·2026-10-30 ·Burak Bakkar, Hana Moalla, Mohamed Salem Jedidi, Haifa Ben Messaoud, Nicolas Lopez Carranza
benchmark similarity 0.70
Abstract

Clinical trial failures are a major barrier to efficient drug development, incurring substantial costs and delaying patient access to effective therapies. Structured approaches such as the Hierarchical Interaction Network (HINT) predict trial outcomes by explicitly modelling interactions between drugs, diseases and protocols, but make limited use of the free text in trial registrations. We evaluate two domain-specific language models, BioBERT (108M parameters) and BioMistral (7B parameters), for phase-level outcome prediction on the TOP benchmark (12,477 trials), representing each trial as text built from ten ClinicalTrials.gov fields. We compare fine-tuning (full fine-tuning for BioBERT, low-rank adaptation for BioMistral) with probing, in which the pretrained model is frozen and only a lightweight classifier is trained on its embeddings. On the held-out test set of each phase, all four language-model variants achieved higher ROC-AUC (0.613--0.772) and PR-AUC (0.649--0.901) than the published HINT results, corresponding to relative PR-AUC gains of 10--20\%. F1 differences were small and mixed, and no model, including HINT, clearly exceeded the F1 of a trivial classifier that predicts success for every trial. Under the configurations tested, probing performed comparably to fine-tuning: fine-tuned models scored highest on ROC-AUC and PR-AUC in Phases I and II, and frozen BioMistral embeddings in Phase III (ROC-AUC 0.772; PR-AUC 0.901), although most differences between variants were below 0.03 and were not tested for significance. These results suggest that pretrained biomedical representations already encode signal relevant to trial outcome, and that probing is a computationally cheaper alternative to fine-tuning for this task.

0.22

TrialJev: Open-Weight Single Pass Eligibility Scoring for Patient Trial Screening

cs.LG ·2026-11-06 ·Omar Ibrahim, Grant Hamblin, Benjamin Haibe-Kains
code/data similarity 0.69
Abstract · 38 pages. Code: https://github.com/oibrahi1/TrialJev. Models: https://huggingface.co/omareng/TrialJev

Clinical trial screening requires assessing large numbers of patient-trial pairs to prioritize candidates for detailed eligibility review, often under restrictions on sharing patient records. We introduce TrialJev, an open-weight eligibility scorer that uses LoRA-adapted Qwen models and a pointer head to score natural-language answer options in a single forward pass, without autoregressive decoding. Trained on TREC Clinical Trials 2021 and evaluated on 6,975 eligible-or-excluded pairs from 50 unseen TREC 2022 synthetic patients, TrialJev achieves 80.97% (Qwen3.5-27B) and 81.84% (Qwen3.8-27B) accuracy, compared with 79.87% and 79.93% for LLMs fine-tuned on the same data to generate verdicts. In matched batch-1 measurements, verdict generation takes 2.45-2.70 times as long as the one-pass inference of TrialJev at 9B-27B. Under a common development-fitted decision correction, the two 27B TrialJev models reach 80.99% and 81.88% accuracy, compared with 81.28% for the proprietary hosted Jev API; paired confidence intervals include zero. TrialJev runs locally on a single GPU, requiring approximately 178 ms per pair at 27B, without transmitting patient text to an external model API. An A/B-logit ablation shows that avoiding decoding, rather than the pointer head alone, accounts for the measured efficiency advantage. TrialJev is intended for first-pass prioritization of candidate trials, complementing rather than replacing explanatory models and clinical review. Evaluation is limited to synthetic patients and implementation-specific timing, and clinical use has not been validated. Adapters, pointer heads, and model cards are released on Hugging Face.

0.22

RECITE: Revising Eligibility Criteria Incorporating Textual Evidence

cs.AI ·2026-10-30 ·Russell Ro, Reza Abbasi-Asl
top venuebenchmark similarity 0.66
Abstract · 18 pages, 4 figures, 4 tables. Extended version of a paper in KDD 2026 (32nd ACM SIGKDD Conference on Knowledge Discovery and Data Mining). …

Overly restrictive eligibility criteria contribute to widespread enrollment failure in clinical trials, yet published recommendations for how specific criteria should be broadened remain disconnected from trial design at scale. We introduce RECITE (Revising Eligibility Criteria Incorporating Textual Evidence), a framework for automated discovery, extraction, and implementation of evidence-based eligibility criteria revisions. RECITE uses protocol amendment documents from ClinicalTrials.gov to construct a dataset of 11,913 curated instances across 5,735 trials, each pairing original criteria with documentary evidence and target revisions. We benchmark fifteen LLM configurations under truncated-to-context-window and retrieval-augmented generation conditions, on a 3,116-instance sample under an LLM-as-judge protocol validated against ten domain experts (judge vs. human quadratic-weighted Cohen's $κ_{qw} = 0.694 \pm 0.096$). The best open-weight model, Gemma 2 9B, achieves $κ_{qw}$-aligned ordinal score $3.0 \pm 0.9$ on a 0--4 scale (normalized 0.742) and the best closed-weight model, GPT-4o, reaches $3.0 \pm 0.8$ (normalized 0.745). Using an agentic literature discovery system, we then identified 44 paper--trial matches across five publications providing trial-design and EC-modification evidence. Our findings suggest that existing clinical knowledge can be operationalized into actionable trial design recommendations.

0.55

Towards AI-Assisted Clinical Trial Matching: Practical Considerations, Multicenter Evaluation, and Real-World Deployment

cs.CL cs.AIcs.CY ·2026-09-01 ·Yin Fang, Qiao Jin, Shubo Tian, Lauren He, Maya Geer +22 more
benchmark similarity 0.66
Abstract · 43 pages, 12 figures

Clinical trials are essential for evidence-based medicine and drug development, but many fail because of insufficient patient enrollment. Although there is growing interest in using AI to support patient recruitment, existing systems largely perform eligibility assessment alone and have rarely been evaluated in real-world workflows. Here we present TrialGPT 2.0, an AI-assisted clinical trial recommendation system improved for responsible real-world deployment. Rather than asking only whether a patient may qualify, the system assesses which trials warrant further consideration given the patient's current clinical needs and local workflow priorities, and provides structured, inspectable explanations for expert review. Importantly, we evaluated TrialGPT 2.0 retrospectively and prospectively across government research, patient-advocacy, academic medical center, and community-based radiation-oncology settings. In retrospective multicenter cohorts comprising 288 cases, TrialGPT 2.0 retrieved at least one clinician-recommended trial in its top 10 recommendations for approximately 91% of cases while reducing clinician screening time by 55.0%. In a six-month prospective evaluation embedded in an active precision oncology tumor board, TrialGPT 2.0 contributed additional trial opportunities missed by the routine workflow, increasing the number of patient cases with at least one final trial recommendation by 90.9%. To support scientific reproducibility, we also developed NIH-TrialBench, a clinician-authored benchmark comprising 126 diverse synthetic patient vignettes and matching scenarios from 11 NIH Institutes and Centers. Together, these findings support the value of AI to assist clinical trial matching by improving clinician efficiency and identifying frequently overlooked trial opportunities, ultimately helping to expand and accelerate accrual to cancer trials.

0.24

Answering clinicians' questions over trial evidence tables with verifiable, feedback-driven language models

cs.AI ·2026-10-01 ·Manan Roy Choudhury, Suparno Roy Chowdhury, Swastik Sahoo, Muhammad Ali Khan, Kaneez Zahra Rubab Khakwani +3 more
published similarity 0.66
Abstract

Systematic reviews condense clinical trials into evidence tables, yet clinicians can interrogate these tables only through database queries, and many questions concern attributes that the table does not record, such as a drug's target class or a harmonised endpoint. Here we introduce FD-SCoPE, a language-model framework that answers both kinds of question, exposes the query, the selected trials and the derivation rule behind every answer, and learns from expert corrections. On an oncology evidence table of 159 immune checkpoint inhibitor trial records, FD-SCoPE completed all 140 clinician-style tasks (alternatives, 90.7-97.9%). For questions needing derived attributes it retrieved 99.3% of relevant trial records at a positive predictive value of 89.8% and outperformed four alternative approaches (derived-value F1 77.7% versus 64.8-73.4%). Corrections on 299 questions, simulated from reference answers, raised F1 on 1,201 unseen questions from 77.9% to 84.9%. Language models coupled with executable queries, verified programs and expert feedback can give clinicians auditable access to trial evidence.

0.32

Designing a Robust LLM-Based Evaluation System for Agentic AI in Drug Discovery Through Human Alignment

cs.LG ·2026-08-21 ·Emma Granqvist, Rocío Mercado, Samuel Genheden
similarity 0.65
Abstract

Agentic large language model (LLM) systems are reshaping scientific workflows in chemistry and drug discovery, but evaluating their open-ended, tool-augmented outputs remains a fundamental bottleneck. The LLM-as-a-Judge paradigm has emerged as a scalable alternative, but existing drug discovery benchmarks deploy LLM judges without validating their alignment with human experts. In this work, we present an LLM-as-a-Judge evaluation framework for ChatInvent, an agentic drug discovery assistant deployed at AstraZeneca, with five contributions. First, we define four output-quality evaluation dimensions---Completeness, Relevancy, Structural Clarity, and Scope Adherence---alongside deterministic Tool Call Correctness checks. Second, we validate the judge through a human alignment study with five expert annotators, comparing Gemini 3.1 Pro, Claude Opus 4.7, GPT-5, and Llama 3.1 70B as candidate judges. Third, we optimize the best-performing judge using few-shot demonstrations of human-annotated examples, improving alignment with the human majority vote from 0.80 to 0.86. Fourth, applying the optimized judge to 70 held-out questions, we surface concrete limitations and find no strong evidence that informal phrasing degrades output quality; it may, however, still be helpful to have the LLM rewrite the original question before querying the agent. Finally, we extend the framework to 38 adversarial questions that are ambiguous, invalid, out-of-scope or ethically sensitive, and show that the agent's refusal behavior is guided by the stated intent of a request. Our framework provides a reusable template for human-aligned evaluation of agentic systems in scientific domains.

0.24

LLM Agents Perform Controlled Experiments Using Simulation Models

cs.AI cs.CLcs.MAcs.SE ·2026-08-22 ·Yuchen Xia, Michael Weyrich, Nasser Jazdi, Johannes Stümpfle, Johannes Sigel +4 more
published similarity 0.64
Abstract · Accepted at the 31st IEEE International Conference on Emerging Technologies and Factory Automation ETFA 2026

Large language models (LLMs) have shown strong capabilities in reasoning, planning, and tool use, but many scientific and engineering tasks require more than plausible text and code generation. They require understanding how a system responds to intervention, which in practice depends on controlled experimentation. In this work, we propose a multi-agent framework that enables LLM agents to conduct controlled experiments with scientific simulation models for pharmaceutical process design. Given a user query and a baseline configuration, the system constructs a structured task representation, designs experiments, executes comparative simulation, interprets the resulting outcomes, and synthesizes evidence-based recommendations for process parameter optimization. By coupling language models with high-fidelity simulation models in an interactive agent framework, the proposed system supports reasoning through intervention, comparison, and observation. As a result, it produces more specific and actionable outputs than language-only reasoning. In an industrial application setting, this advantage is reflected in higher output specificity as well as improved user-rated correctness and helpfulness. Ablation studies and visualized case analyses further demonstrate the effectiveness and practical utility of simulation-integrated experimental reasoning.

0.33